Development of recombinant stable house dust mite allergen Der p 3 molecules for component-resolved diagnosis and specific immunotherapy

Clinical and Experimental Allergy

Volumn 45, Issue 4, 2015, Pages 823-834

  Bouaziz, A ^a   Walgraffe, D ^b   Bouillot, C ^b   Herman, J ^a   Foguenne, J ^a   Gothot, A ^a   Louis, R ^a   Hentges, F ^c   Jacquet, A ^d   Mailleux, A C ^e   Chevigne A ^a,c   Galleni, M ^a   Adam, E ^b   Dumez, M E ^a,c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Der p 3; Diagnosis; Hypoallergen; Inactive enzyme; Recombinant mite allergen; Specific immunotherapy

Indexed keywords

ALLERGEN DER P 3; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; RECOMBINANT ALLERGEN; UNCLASSIFIED DRUG; ALLERGEN; ARTHROPOD PROTEIN; CYTOKINE; DERMATOPHAGOIDES PTERONYSSINUS ANTIGEN P 3; IMMUNOGLOBULIN G; PROTEIN BINDING; RECOMBINANT PROTEIN; SERINE PROTEINASE;

ALLERGENICITY; ALLERGY RAPID TEST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOLYSIS; BASOPHIL DEGRANULATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; DRUG BINDING; FEMALE; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; IMMUNOTHERAPY; KOMAGATAELLA PASTORIS; LEUKEMIA; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIZATION; ANIMAL; BASOPHIL; BLOOD; DERMATOPHAGOIDES PTERONYSSINUS; HYPERSENSITIVITY; IMMUNIZATION; IMMUNOLOGY; METABOLISM; PROTEIN DEGRADATION;

ALLERGENS; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ARTHROPOD PROTEINS; BASOPHILS; CYTOKINES; DERMATOPHAGOIDES PTERONYSSINUS; FEMALE; HUMANS; HYPERSENSITIVITY; IMMUNIZATION; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOTHERAPY; PROTEIN BINDING; PROTEOLYSIS; RATS; RECOMBINANT PROTEINS; SERINE ENDOPEPTIDASES;

EID: 84925071369     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12452     Document Type: Article

References (38)

1. Bousquet PJ, Chinn S, Janson C, Kogevinas M, Burney P, Jarvis D. Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I. Allergy 2007; 62:301-9.
2. Gaffin JM, Phipatanakul W. The role of indoor allergens in the development of asthma. Curr Opin Allergy Clin Immunol 2009; 9:128-35.
3. Thomas WR. Geography of house dust mite allergens. Asian Pac J Allergy Immunol 2010; 28:211-24.
4. Moingeon P, Mascarell L. Novel routes for allergen immunotherapy: safety, efficacy and mode of action. Immunotherapy 2012; 4:201-12.
5. Cox L, Nelson H, Lockey R et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127(1 Suppl):S1-55.
6. Chapman MD, Ferreira F, Villalba M et al. The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. J Allergy Clin Immunol 2008; 122:882-9 e2.
7. van Ree R, Chapman MD, Ferreira F et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 2008; 63:310-26.
8. Filep S, Tsay A, Vailes L et al. A multi-allergen standard for the calibration of immunoassays: CREATE principles applied to eight purified allergens. Allergy 2012; 67:235-41.
9. Casset A, Mari A, Purohit A et al. Varying allergen composition and content affects the in vivo allergenic activity of commercial Dermatophagoides pteronyssinus extracts. Int Arch Allergy Immunol 2012; 159:253-62.
10. Jacquet A. The role of the house dust mite-induced innate immunity in development of allergic response. Int Arch Allergy Immunol 2011; 155:95-105.
11. Thomas WR. The advent of recombinant allergens and allergen cloning. J Allergy Clin Immunol 2011; 127:855-9.
12. Bordas-Le Floch V, Bussieres L, Airouche S et al. Expression and characterization of natural-like recombinant Der p 2 for sublingual immunotherapy. Int Arch Allergy Immunol 2012; 158:157-67.
13. Lucas JM. Microarrays: molecular allergology and nanotechnology for personalised medicine (II). Allergol Immunopathol (Madr) 2010; 38:217-23.
14. Pauli G, Malling HJ. Allergen-specific immunotherapy with recombinant allergens. Curr Top Microbiol Immunol 2011; 352:43-54.
15. Valenta R, Niespodziana K, Focke-Tejkl M et al. Recombinant allergens: what does the future hold? J Allergy Clin Immunol 2011; 127:860-4.
16. Valenta R, Linhart B, Swoboda I, Niederberger V. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy 2011; 66:775-83.
17. Hales BJ, Martin AC, Pearce LJ et al. IgE and IgG anti-house dust mite specificities in allergic disease. J Allergy Clin Immunol 2006; 118:361-7.
18. Weghofer M, Thomas WR, Kronqvist M et al. Variability of IgE reactivity profiles among European mite allergic patients. Eur J Clin Invest 2008; 38:959-65.
19. Shakib F, Ghaemmaghami AM, Sewell HF. The molecular basis of allergenicity. Trends Immunol 2008; 29:633-42.
20. Jacquet A. Interactions of airway epithelium with protease allergens in the allergic response. Clin Exp Allergy 2011; 41:305-11.
21. Gregory LG, Lloyd CM. Orchestrating house dust mite-associated allergy in the lung. Trends Immunol 2011; 32:402-11.
22. King C, Brennan S, Thompson PJ, Stewart GA. Dust mite proteolytic allergens induce cytokine release from cultured airway epithelium. J Immunol 1998; 161:3645-51.
23. Wan H, Winton HL, Soeller C et al. The transmembrane protein occludin of epithelial tight junctions is a functional target for serine peptidases from faecal pellets of Dermatophagoides pteronyssinus. Clin Exp Allergy 2001; 31:279-94.
24. Sun G, Stacey MA, Schmidt M, Mori L, Mattoli S. Interaction of mite allergens Der p3 and Der p9 with protease-activated receptor-2 expressed by lung epithelial cells. J Immunol 2001; 167:1014-21.
25. Adam E, Hansen KK, Astudillo Fernandez O et al. The house dust mite allergen Der p 1, unlike Der p 3, stimulates the expression of interleukin-8 in human airway epithelial cells via a proteinase-activated receptor-2-independent mechanism. J Biol Chem 2006; 281:6910-23.
26. Stewart GA, Ward LD, Simpson RJ, Thompson PJ. The group III allergen from the house dust mite Dermatophagoides pteronyssinus is a trypsin-like enzyme. Immunology 1992; 75:29-35.
27. Smith WA, Chua KY, Kuo MC, Rogers BL, Thomas WR. Cloning and sequencing of the Dermatophagoides pteronyssinus group III allergen, Der p III. Clin Exp Allergy 1994; 24:220-8.
28. Dumez ME, Teller N, Mercier F et al. Activation mechanism of recombinant Der p 3 allergen zymogen: contribution of cysteine protease Der p 1 and effect of propeptide glycosylation. J Biol Chem 2008; 283:30606-17.
29. Takai T, Kato T, Yasueda H, Okumura K, Ogawa H. Analysis of the structure and allergenicity of recombinant pro- and mature Der p 1 and Der f 1: major conformational IgE epitopes blocked by prodomains. J Allergy Clin Immunol 2005; 115:555-63.
30. Walgraffe D, Matteotti C, El Bakkoury M et al. A hypoallergenic variant of Der p 1 as a candidate for mite allergy vaccines. J Allergy Clin Immunol 2009; 123:1150-6.
31. Chevigne A, Barumandzadeh R, Groslambert S et al. Relationship between propeptide pH unfolding and inhibitory ability during ProDer p 1 activation mechanism. J Mol Biol 2007; 374:170-85.
32. Chevigne A, Dumez ME, Dumoulin M, Matagne A, Jacquet A, Galleni M. Comparative study of mature and zymogen mite cysteine protease stability and pH unfolding. Biochim Biophys Acta 2010; 1800:937-45.
33. Dumez ME, Herman J, Campisi V et al. The proline-rich motif of the proDer p 3 allergen propeptide is crucial for protease-protease interaction. PLoS ONE 2013; 8:e68014.
34. Sturm EM, Kranzelbinder B, Heinemann A, Groselj-Strele A, Aberer W, Sturm GJ. CD203c-based basophil activation test in allergy diagnosis: characteristics and differences to CD63 upregulation. Cytometry B Clin Cytom 2010; 78:308-18.
35. Asturias JA, Ibarrola I, Arilla MC et al. Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Clin Exp Allergy 2009; 39:1088-98.
36. Nakajima H, Takatsu K. Role of cytokines in allergic airway inflammation. Int Arch Allergy Immunol 2007; 142:265-73.
37. Schmidlin F, Amadesi S, Dabbagh K et al. Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol 2002; 169:5315-21.
38. Chen CL, Wang SD, Zeng ZY et al. Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma. J Allergy Clin Immunol 2006; 118:105-12.